Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Qiagen and Max Planck team up for test predicting risk of latent TB progression

This article was originally published in Clinica

Executive Summary

Molecular diagnostics firm Qiagen and the Max Planck Institute for Infection Biology are developing a test to predict the risk of latent tuberculosis infection progressing to active disease. The new test should become available in 2013 or later, and will be commercialised by Qiagen. Financial terms of the deal were not disclosed.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts